Takeda Pharmaceutical Company Limited Share Price NYSE
Stocks
TAK
US8740602052
Pharmaceuticals
OTC Markets Traded|
Market Closed -
NYSE
01:30:03 27/10/2026 am IST
|
5-day change | 1st Jan Change | ||
| 20.43 USD | +0.94% |
|
+4.18% | +31.05% |
| 26/10 | Takeda Pharmaceutical Eyes 2027 Japan Filing for Gastric Cancer Treatment | MT |
| 26/10 | Takeda to seek Japan approval for gastric cancer drug next year | RE |
| Market Cap | 10,30200Cr 6.54TCr 5.85TCr 5.41TCr 4.9TCr 9.17TCr 6,22100Cr 9.32TCr 65TCr 26TCr 3,25400Cr 25TCr 24TCr | P/E 2027 * |
51.1x | P/E 2028 * | 32.4x |
|---|---|---|---|---|---|
| Enterprise Value | 14,21000Cr 9.02TCr 8.06TCr 7.46TCr 6.76TCr 13TCr 8,58000Cr 13TCr 90TCr 36TCr 4,48800Cr 34TCr 33TCr | EV / Sales 2027 * |
3.02x | EV / Sales 2028 * | 2.92x |
| Free-Float |
99.18% | Yield 2027 * |
3.17% | Yield 2028 * | 3.23% |
| Markets | Quality | ||
|---|---|---|---|
NYSE
| TAK | Delayed | |
CBOE
| TAK | Real-time | |
|
London S.E.
| 0A87 | Delayed | |
|
Mexican S.E.
| TAK N | End-of-day quote | |
|
Tradegate
| TKDA | Real-time | |
|
Deutsche Boerse AG
| TKDA | Delayed | |
|
Börse Stuttgart
| TKDA | Delayed | |
|
Boerse Muenchen
| TKDA | Real-time |
Last Transcript: Takeda Pharmaceutical Company Limited
| 1 day | +0.94% | ||
| 1 week | +4.18% | ||
| Current month | +12.31% | ||
| 1 month | +8.32% | ||
| 3 months | +18.50% | ||
| 6 months | +22.85% | ||
| Current year | +31.05% |
| 1 week | 19.9 |  | 20.55 |
| 1 month | 17.75 | | 20.55 |
| Current year | 14.84 | | 20.55 |
| 1 year | 12.99 | | 20.55 |
| 3 years | 12.58 | | 20.55 |
| 5 years | 12.28 | | 20.55 |
| 10 years | 12.28 | | 31.29 |
| Manager | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 56 | 01/01/2025 | |
Mikuno Furuta
DFI | Director of Finance/CFO | 48 | 01/04/2024 |
Gabriele Ricci
CTO | Chief Tech/Sci/R&D Officer | 48 | 01/02/2022 |
| Director | Title | Age | Since |
|---|---|---|---|
Andrew Plump
BRD | Director/Board Member | 61 | 01/06/2015 |
Steven Gillis
BRD | Director/Board Member | 73 | 01/01/2019 |
Mikuno Furuta
BRD | Director/Board Member | 48 | 01/06/2024 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +0.94% | +4.18% | - | - | 6.54TCr | |
| +0.45% | +3.13% | +54.96% | +125.16% | 1,14000Cr | |
| +0.94% | +4.93% | +39.86% | +78.72% | 64TCr | |
| +0.39% | +1.44% | +25.77% | +97.48% | 51TCr | |
| -0.61% | +1.05% | +47.34% | +65.72% | 38TCr | |
| -3.21% | -2.10% | +60.72% | +33.22% | 35TCr | |
| +0.45% | +1.11% | +23.98% | +52.70% | 29TCr | |
| -0.68% | +1.17% | +1.75% | +26.10% | 27TCr | |
| +1.22% | +4.63% | +52.40% | +64.85% | 24TCr | |
| +1.70% | +3.67% | +31.21% | +102.15% | 20TCr | |
| Average | +0.06% | +2.92% | +37.56% | +71.79% | 44.6TCr | |
| Weighted average by Cap. | -0.14% | +2.98% | +41.53% | +84.04% |
| 2027 * | 2028 * | |
|---|---|---|
| Net sales | 4,70200Cr 2.98TCr 2.67TCr 2.47TCr 2.24TCr 4.18TCr 2,83900Cr 4.25TCr 30TCr 12TCr 1,48500Cr 11TCr 11TCr | 4,79600Cr 3.04TCr 2.72TCr 2.52TCr 2.28TCr 4.27TCr 2,89600Cr 4.34TCr 30TCr 12TCr 1,51500Cr 11TCr 11TCr |
| Net income | 20TCr 124.61Cr 111.42Cr 103.09Cr 93Cr 174.69Cr 12TCr 177.55Cr 1.24TCr 490.69Cr 6.2TCr 467.68Cr 457.69Cr | 32TCr 205.02Cr 183.33Cr 169.61Cr 153.57Cr 287.43Cr 20TCr 292.13Cr 2.04TCr 807.35Cr 10TCr 769.49Cr 753.04Cr |
| Net Debt | 3,90700Cr 2.48TCr 2.22TCr 2.05TCr 1.86TCr 3.48TCr 2,35900Cr 3.53TCr 25TCr 9.77TCr 1,23400Cr 9.31TCr 9.11TCr | 3,70500Cr 2.35TCr 2.1TCr 1.95TCr 1.76TCr 3.3TCr 2,23700Cr 3.35TCr 23TCr 9.26TCr 1,17000Cr 8.83TCr 8.64TCr |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26/26/26 | $20.43 | +0.94% | 23,67,366 |
| 23/26/23 | $20.24 | -0.59% | 20,99,212 |
| 22/26/22 | $20.36 | +2.16% | 34,61,934 |
| 21/26/21 | $19.93 | -0.75% | 16,71,406 |
| 20/26/20 | $20.08 | +2.40% | 29,07,340 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- 4502 Stock
- TAK Stock
Select your edition
All financial news and data tailored to specific country editions
